PE20080677A1 - Inhibidores de pirrolotriazina cinaza - Google Patents

Inhibidores de pirrolotriazina cinaza

Info

Publication number
PE20080677A1
PE20080677A1 PE2007000874A PE2007000874A PE20080677A1 PE 20080677 A1 PE20080677 A1 PE 20080677A1 PE 2007000874 A PE2007000874 A PE 2007000874A PE 2007000874 A PE2007000874 A PE 2007000874A PE 20080677 A1 PE20080677 A1 PE 20080677A1
Authority
PE
Peru
Prior art keywords
alkyl
cinaza
pirrolo
ilamino
triazin
Prior art date
Application number
PE2007000874A
Other languages
English (en)
Inventor
David B Frennesson
Walter Lewis Johnson
David R Langley
Harold Mastalerz
Xiaopeng Sang
Mark G Saulnier
Upender Velaparthi
Dolatrai M Vyas
Mark D Wittman
Kurt Zimmermann
Guifen Zhang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20080677A1 publication Critical patent/PE20080677A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE Q1 ES ARILO SUSTITUIDO, O NO, HETEROARILO SUSTITUIDO O NO; X ES C=O, C=S, CH2, ENTRE OTROS; R1, R2 Y R3 SON CADA UNO H, ALQUILO, CICLOALQUILO, HIDROXI, ENTRE OTROS; R4 ES H, ALQUILO, HALOALQUILO, OXO, ARILOXI, ENTRE OTROS; R5 ES H, HALOGENO, CIANO, ENTRE OTROS; R6 ES H, ALQUILO, HIDROXI, ALQUILIDENO, ENTRE OTROS; n ES 0-6; R7 Y R8 SON CADA UNO H, ALQUILO, CICLOALQUILO, ARILO, HETEROARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (S)-1-(4-(5-CICLOPROPIL-1H-PIRAZOL-3-ILAMINO)PIRROLO[1,2-f][1,2,4]TRIAZIN-2-IL)-N-(TETRAHIDRO-2H-PIRAN-4-IL)PIRROLIDINA-2-CARBOXAMIDA; (R)-N-BENCIL-1-(4-(5-CICLOPROPIL-1H-PIRAZOL-3-ILAMINO)PIRROLO[1,2-f][1,2,4]TRIAZIN-2-IL)PIRROLIDINA-2-CARBOXAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA CINASA IGF-1R UTILES EN EL TRATAMIENTO DE CANCER, DIABETES, ACROMEGALIA, ENTRE OTROS
PE2007000874A 2006-07-07 2007-07-05 Inhibidores de pirrolotriazina cinaza PE20080677A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81917106P 2006-07-07 2006-07-07

Publications (1)

Publication Number Publication Date
PE20080677A1 true PE20080677A1 (es) 2008-06-26

Family

ID=38671050

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000874A PE20080677A1 (es) 2006-07-07 2007-07-05 Inhibidores de pirrolotriazina cinaza

Country Status (26)

Country Link
US (4) US7534792B2 (es)
EP (1) EP2041138B1 (es)
JP (1) JP5185930B2 (es)
KR (1) KR101443400B1 (es)
CN (1) CN101511835B (es)
AR (1) AR061873A1 (es)
AU (1) AU2007269163B2 (es)
BR (1) BRPI0714359A2 (es)
CA (1) CA2657594C (es)
CL (1) CL2007001995A1 (es)
CO (1) CO6220940A2 (es)
DK (1) DK2041138T3 (es)
EA (1) EA018322B1 (es)
ES (1) ES2493566T3 (es)
HR (1) HRP20140688T1 (es)
IL (1) IL196033A0 (es)
MX (1) MX2008016517A (es)
NO (1) NO342385B1 (es)
NZ (1) NZ574189A (es)
PE (1) PE20080677A1 (es)
PL (1) PL2041138T3 (es)
PT (1) PT2041138E (es)
SI (1) SI2041138T1 (es)
TW (1) TWI393722B (es)
WO (1) WO2008005956A2 (es)
ZA (1) ZA200900109B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95298C2 (ru) * 2006-07-07 2011-07-25 Бьёрингер Ингельхайм Интернациональ Гмбх Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
NZ574189A (en) * 2006-07-07 2011-03-31 Bristol Myers Squibb Co Pyrrolotriazine kinase inhibitors
EP2134716A1 (en) * 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8492328B2 (en) * 2007-05-17 2013-07-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
WO2009003998A2 (en) * 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
PE20090837A1 (es) * 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
WO2009111531A1 (en) * 2008-03-06 2009-09-11 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW201018670A (en) 2008-09-29 2010-05-16 Boehringer Ingelheim Int New chemical compounds
CN102245610B (zh) * 2008-10-08 2014-04-30 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
EP2376491B1 (en) 2008-12-19 2015-03-04 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
EP2494070A2 (en) 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
WO2011083391A2 (en) 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
JP2013518889A (ja) * 2010-02-03 2013-05-23 ブリストル−マイヤーズ スクイブ カンパニー （Ｓ）−１−（４−（５−シクロプロピル−１Ｈ−ピラゾール−３−イルアミノ）ピロロ［１，２−ｆ］［１，２，４］トリアジン−２−イル）−Ｎ−（６−フルオロピリジン−３−イル）−２−メチルピロリジン−２−カルボキサミドの結晶形
JP5093527B2 (ja) * 2010-02-10 2012-12-12 日本電気株式会社 複合光導波路、波長可変フィルタ、波長可変レーザ、および光集積回路
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
JP5752232B2 (ja) 2010-03-31 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
CN102584828B (zh) * 2011-01-14 2016-01-27 上海艾力斯医药科技有限公司 吡咯烷[3，4-d]嘧啶衍生物、制备方法及其应用
US20140309229A1 (en) 2011-10-13 2014-10-16 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
AR089653A1 (es) 2011-10-25 2014-09-10 Shionogi & Co Derivados heterociclicos que tienen actividad antagonista del receptor de pgd2
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
WO2014105958A2 (en) * 2012-12-26 2014-07-03 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
EP2970231A1 (en) 2013-03-15 2016-01-20 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
HUE059041T2 (hu) 2013-10-17 2022-10-28 Blueprint Medicines Corp Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására
WO2015081783A1 (zh) * 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
WO2015126808A2 (en) * 2014-02-18 2015-08-27 Baldwin John J Hbv assay
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CN104974163B (zh) * 2014-04-14 2017-11-07 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
BR112018001190A2 (pt) * 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
KR20180096621A (ko) 2015-12-18 2018-08-29 이그니타, 인코포레이티드 암의 치료용 조합물
CN109311886B (zh) * 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
US11058115B2 (en) 2017-01-10 2021-07-13 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
JP7098630B2 (ja) 2017-01-10 2022-07-11 バイエル・アクチエンゲゼルシヤフト 有害生物防除剤としてのヘテロサイクレン誘導体
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
EP3392267A1 (en) 2017-04-18 2018-10-24 Myr GmbH Therapy of atherosclerosis, primary biliary cirrhosis and nrlp3 inflammasome-associated disease by htcp inhibitors
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
CN110913842A (zh) 2017-07-19 2020-03-24 伊尼塔公司 包括恩曲替尼的药物组合物
EP3697390A1 (en) 2017-10-17 2020-08-26 Ignyta, Inc. Pharmaceutical compositions and dosage forms
CA3136802A1 (en) 2019-04-12 2020-10-15 Blueprint Medicines Corporation Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
US20220315581A1 (en) * 2019-06-14 2022-10-06 Medshine Discovery Inc. Fused ring compound as fgfr and vegfr dual inhibitor
WO2021257863A1 (en) * 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
KR102612407B1 (ko) * 2021-01-14 2023-12-11 환인제약 주식회사 Ｂｍｓ－７５４８０７ 화합물을 유효성분으로 포함하는 신경염증성 질환의 예방 또는 치료용 약학적 조성물
CN112679407B (zh) * 2021-03-17 2021-06-04 南京桦冠生物技术有限公司 一种手性5-取代脯氨酸类化合物的制备方法
CA3233636A1 (en) * 2021-09-29 2023-04-06 Repare Therapeutics Inc. N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
DK1183033T3 (da) 1999-05-21 2006-06-06 Bristol Myers Squibb Co Pyrrolotriazininhibitorer af kinaser
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003265349A1 (en) * 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
NZ574189A (en) * 2006-07-07 2011-03-31 Bristol Myers Squibb Co Pyrrolotriazine kinase inhibitors
US7531539B2 (en) * 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2393410T3 (es) 2006-08-09 2012-12-21 Bristol-Myers Squibb Company Pirrolotriazinas inhibidoras de quinasas
WO2008057994A2 (en) 2006-11-03 2008-05-15 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
CA2657594C (en) 2012-01-17
EA018322B1 (ru) 2013-07-30
AR061873A1 (es) 2008-09-24
DK2041138T3 (da) 2014-08-11
WO2008005956A3 (en) 2008-03-06
PT2041138E (pt) 2014-10-07
NZ574189A (en) 2011-03-31
US8263765B2 (en) 2012-09-11
US20110124623A1 (en) 2011-05-26
AU2007269163A1 (en) 2008-01-10
US20090239838A1 (en) 2009-09-24
KR101443400B1 (ko) 2014-10-02
BRPI0714359A2 (pt) 2013-02-26
US7534792B2 (en) 2009-05-19
AU2007269163B2 (en) 2011-07-28
TW200813059A (en) 2008-03-16
EP2041138B1 (en) 2014-06-25
US20080009497A1 (en) 2008-01-10
TWI393722B (zh) 2013-04-21
US7879855B2 (en) 2011-02-01
NO342385B1 (no) 2018-05-14
KR20090027764A (ko) 2009-03-17
SI2041138T1 (sl) 2014-08-29
PL2041138T3 (pl) 2014-11-28
CA2657594A1 (en) 2008-01-10
US8592579B2 (en) 2013-11-26
ZA200900109B (en) 2010-03-31
US20120302747A1 (en) 2012-11-29
NO20090025L (no) 2009-02-02
IL196033A0 (en) 2009-09-01
JP5185930B2 (ja) 2013-04-17
JP2009542814A (ja) 2009-12-03
CL2007001995A1 (es) 2008-01-25
CO6220940A2 (es) 2010-11-19
EA200900152A1 (ru) 2009-06-30
EP2041138A2 (en) 2009-04-01
CN101511835B (zh) 2013-11-27
MX2008016517A (es) 2009-01-19
WO2008005956A2 (en) 2008-01-10
HRP20140688T1 (hr) 2014-10-24
ES2493566T3 (es) 2014-09-12
CN101511835A (zh) 2009-08-19

Similar Documents

Publication Publication Date Title
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20080542A1 (es) Inhibidores del virus de la hepatitis c
PE20090964A1 (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b
PE20080139A1 (es) Compuestos de pirrolotriazina anilina como inhibidores de cinasa
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20060664A1 (es) Amidas biciclicas como inhibidores de cinasa
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20071094A1 (es) Derivados 1-ortoflurofenil sustituidos 1,2,5-tiadiazolidindionas como inhibidores de ptpasa
PE20080772A1 (es) Nuevos derivados de bipiridina sustituidos y su uso
EA200701114A1 (ru) Азоловые производные с антимускариновой активностью
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20051095A1 (es) DERIVADOS 1H-TIENO[2,3-c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
EA200701756A1 (ru) Соль производного пролина, её сольват и способ её получения
PE20081530A1 (es) Nuevos compuestos 617
PE20110102A1 (es) Derivados de n-(2-oxo-2-pirrolidinil-1-il)etil-2-amino-acetamida como inhibidores de proteinas de apoptosis (iap)
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
PE20071100A1 (es) Derivados de azepinoindol como agentes farmaceuticos
PE20060873A1 (es) Compuestos de quinolina heteroaromaticos
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso

Legal Events

Date Code Title Description
FG Grant, registration